Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes

doi:10.4254/wjh.125505

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

(4)

(6)

(0)

(39)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Oct 27, 2026; 18(10): 125505
Published online Oct 27, 2026. doi: 10.4254/wjh.125505

Table 7 Spearman correlations of clinical, laboratory, and lipogenesis-related biomarkers with liver stiffness and hepatic steatosis (ultrasound-guided attenuation parameter) at baseline and after 6 months of sodium-glucose cotransporter 2 inhibitor therapy

Parameter	Baseline		6 months
Parameter	2D-SWE	UGAP	2D-SWE	UGAP
Age (year)	0.079 (0.53)	-0.288 (0.02)^a	-0.028 (0.82)	-0.254 (0.04)^a
BMI (kg/m²)	0.563 (< 0.001)^a	0.467 (< 0.001)^a	0.467 (< 0.001)^a	0.538 (< 0.001)^a
WC (cm)	0.582 (< 0.001)^a	0.467 (< 0.001)^a	0.652 (< 0.001)^a	0.551 (< 0.001)^a
ALT (U/L)	0.172 (0.16)	0.458 (< 0.001)^a	0.326 (0.01)^a	0.465 (< 0.001)^a
AST (U/L)	0.138 (0.27)	0.379 (< 0.001)^a	0.258 (0.03)^a	0.311 (0.01)^a
ALP (U/L)	-0.072 (0.56)	-0.012 (0.93)	0.079 (0.53)	0.001 (0.99)
AST/ALT ratio	-0.104 (0.40)	-0.324 (0.01)^a	-0.215 (0.08)	-0.423 (< 0.001)^a
GGT (U/L)	0.167 (0.18)	0.513 (< 0.001)^a	0.285 (0.02)^a	0.517 (< 0.001)^a
Cholesterol (mmol/L)	-0.125 (0.31)	0.110 (0.40)	-0.249 (0.04)^a	-0.085 (0.50)
HDL (mmol/L)	-0.125 (0.31)	-0.132 (0.31)	-0.250 (0.04)^a	-0.323 (0.01)^a
LDL (mmol/L)	-0.063 (0.61)	0.048 (0.71)	-0.249 (0.05)	-0.05 (0.69)
Triglycerides (mmol/L)	0.057 (0.65)	0.369 (< 0.001)^a	0.161 (0.20)	0.371 (< 0.001)^a
UGAP	0.357 (0.005)^a	-	0.422 (< 0.001)^a	-
PPAR-γ	-0.068 (0.58)	-0.047 (0.72)	-0.233 (0.06)	0.045 (0.72)
PPAR-α	-0.016 (0.90)	-0.183 (0.16)	0.023 (0.85)	0.143 (0.25)
SREBP-1c	-0.080 (0.52)	-0.037 (0.78)	-0.127 (0.31)	0.050 (0.69)
MTTP	0.055 (0.66)	0.017 (0.89)	-0.268 (0.03)^a	0.066 (0.60)
NFS	0.334 (0.01)^a	0.050 (0.71)	0.236 (0.06)	-0.032 (0.80)
FIB-4	0.057 (0.65)	-0.141 (0.28)	0.014 (0.91)	-0.201 (0.10)

^aP < 0.05.

Values are Spearman’s correlation coefficients (ρ) with corresponding P-values in parentheses. Concentrations of lipogenesis-related biomarkers were measured in ng/L, two-dimensional shear wave elastography in kPa; ultrasound-guided attenuation parameter in dB/cm/MHz. 2D-SWE: Two-dimensional shear wave elastography; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; BMI: Body mass index; FIB-4: Fibrosis-4 index; GGT: Gamma-glutamyl transferase; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; MTTP: Microsomal triglyceride transfer protein; NFS: Non-alcoholic fatty liver fibrosis score; PPAR-γ: Peroxisome proliferator-activated receptor gamma; PPAR-α: Peroxisome proliferator-activated receptor alpha; SREBP-1c: Sterol regulatory element-binding protein 1c; UGAP: Ultrasound-guided attenuation parameter; WC: Waist circumference.

Full Size Table

Citation: Khaznadar F, Bojanić K, Khaznadar O, Jurić A, Hefer M, Kralik K, Petrović A, Hrženjak A, Lončar A, Steiner J, Smolić M, Smolić R. Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes. World J Hepatol 2026; 18(10): 125505
URL: https://www.wjgnet.com/1948-5182/full/v18/i10/125505.htm
DOI: https://dx.doi.org/10.4254/wjh.125505

Khaznadar F, Bojanić K, Khaznadar O, Jurić A, Hefer M, Kralik K, Petrović A, Hrženjak A, Lončar A, Steiner J, Smolić M, Smolić R. Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes. World J Hepatol 2026; 18(10): 125505 [DOI: 10.4254/wjh.125505]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.